Cytotoxic agents are conventionally dosed on the basis of the maximum tolerated dose defined in phase I trials. A study assessing adverse events in over 2,000 patients treated with molecularly targeted agents suggests a need to redefine criteria for dosing of molecularly targeted agents, which should be based on randomized, dose-ranging phase II trials.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Dose Finding in Oncology: What is Impeding Coming of Age?
Pharmaceutical Research Open Access 26 April 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
09 September 2014
In the version of this article published in print, references 1 and 8 contained incorrect details. These errors have been corrected for the HTML and PDF versions of the article published online.
References
Postel-Vinay, S. et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents—Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. Eur. J. Cancer 50, 2040–2049 (2014).
Dose-response information to support drug registration E4. ICH Harmonised Tripartite Guidline [online], (1994).
Atkins, M. B. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909–918 (2004).
Jonat, W. et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 32A, 404–412 (1996).
Shaw, A. T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189–1197 (2014).
Ceritinib drug safety data. FDA Center for Drug Evaluation and Research [online], (2014).
Ceritinib drug safety data summary review. FDA Center for Drug Evaluation and Research [online], (2014).
Center for Drug Evaluation and Research. Application number: 205755Orig1s000 Medical Reviews. FDA Center for Drug Evaluation and Research [online], (2014).
Szmulewitz, R. Z. & Ratain, M. J. Playing Russian roulette with tyrosine kinase inhibitors. Clin. Pharmacol. Ther. 93, 242–244 (2013).
Kremer, J. M. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum. 60, 1895–1905 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ratain, M. Redefining the primary objective of phase I oncology trials. Nat Rev Clin Oncol 11, 503–504 (2014). https://doi.org/10.1038/nrclinonc.2014.135
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.135
